Huxley Health Inc. Introduces Aerasyn Biotech Division, Expands Leadership and Scalable IP Platform, Engages Capital Partner for Up to $15M Financing and Prepares to Go Public Amid Growing U.S. Policy and Public Discourse on Psychedelics
Toronto, Ontario - Newsfile Corp. - April 20, 2026 - Huxley Health Inc. ("Huxley" or the "Company"), together with its Aerasyn Biotech division, a biotechnology platform advancing next-generation therapeutics through AI-guided discovery, advanced synthesis, and proprietary formulation technologies, today announced a series of coordinated strategic developments that significantly strengthen its leadership team, intellectual property platform, and capital markets positioning.
